An open label, phase III, randomised, multicenter study to evaluate the efficacy and safety of Rivaroxaban in prevention of recurrent thrombosis in patients with antiphospholipid syndrome

Trial Profile

An open label, phase III, randomised, multicenter study to evaluate the efficacy and safety of Rivaroxaban in prevention of recurrent thrombosis in patients with antiphospholipid syndrome

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Antiphospholipid syndrome; Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jul 2017 New trial record
    • 17 Jun 2017 Trial design of the study presented at the 18th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top